Epizyme, Inc. has signed a lease to expand at 400 Technology Square in Cambridge, Mass.
Epizyme, Inc., a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers, currently leases 32,403 rentable square feet in the building. The new lease expands the original lease by adding 10,663 rentable square feet on the building’s sixth floor.
The building landlord is ARE-TECH SQUARE, LLC, an affiliate of Alexandria Real Estate Equities.
Richards Barry Joyce and Partners and Cushman & Wakefield of Massachusetts brokered the transaction, according to the lease.
Built in 1967, 400 Technology Square contains 194,776 rentable square feet of Class A office space. The building was renovated in 1999. One of seven laboratory/office facilities comprising the 1.2 million square foot Alexandria Technology Square, 400 Technology Square is adjacent to Massachusetts Institute of Technology, the Broad Institute and the Whitehead Institute.
Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme’s targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.